According to the research report, the global antibody drug conjugates market size is expected to touch USD 25.46 Billion by 2032, from USD 9.04 Billion in 2022, growing with a significant CAGR of 10.91% from 2023 to 2032.
The antibody drug conjugates report offers
a comprehensive study of the current state expected at the major drivers,
market strategies, and key vendors’ growth. The report presents energetic
visions to conclude and study the market size, market hopes, and competitive
surroundings. The research also focuses on the important achievements of the
market, research & development, and regional growth of the leading
competitors operating in the market. The current trends of the global antibody
drug conjugates in conjunction with the geographical landscape of this vertical
have also been included in this report.
The report offers intricate dynamics about
different aspects of the global antibody drug conjugates market, which aids
companies operating in the market in making strategic development decisions.
The study also elaborates on significant changes that are highly anticipated to
configure growth of the global antibody drug conjugates during the forecast
period. It also includes a key indicator assessment that highlights growth
prospects of this market and estimates statistics related to growth of the
market in terms of value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/2645
| Report Coverage | Details |
| Market Size in 2023 | USD 10.03 Billion |
| Market Size by 2032 | USD 25.46 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 10.91% |
| Largest Market | North America |
| Second Largest Market | Europe |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Application and By Technology |
This study covers a detailed segmentation
of the global antibody drug conjugates market, along with key information and a
competition outlook. The report mentions company profiles of players that are
currently dominating the global antibody drug conjugates market, wherein various
developments, expansions, and winning strategies practiced and implemented by
leading players have been presented in detail.
Key Players
- Takeda Pharmaceutical Company Limited
- Pfizer Inc
- GlaxoSmithKline Plc
- AstraZeneca
- Seagen Inc
- ADC Therapeutics
- Gilead Sciences Inc
- F. Hoffmann-La Roche Ltd
Market Segmentation
- Blood Cancer
- Breast Cancer
- Urothelial Cancer
- Bladder Cancer
By Technology
- Cleavable
- Non-cleavable
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- The Middle East and Africa
Research Methodology
The research methodology adopted by
analysts for compiling the global antibody drug conjugates report is based on
detailed primary as well as secondary research. With the help of in-depth
insights of the market-affiliated information that is obtained and legitimated
by market-admissible resources, analysts have offered riveting observations and
authentic forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market association
publications, and company websites to obtain the necessary understanding of the
global antibody drug conjugates market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Antibody Drug Conjugates Market
5.1. COVID-19 Landscape: Antibody Drug Conjugates Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Antibody Drug Conjugates Market, By Application
8.1. Antibody Drug Conjugates Market, by Application, 2023-2032
8.1.1. Blood Cancer
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Breast Cancer
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Urothelial Cancer
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Bladder Cancer
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Antibody Drug Conjugates Market, By Technology
9.1. Antibody Drug Conjugates Market, by Technology, 2023-2032
9.1.1. Cleavable
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Non-cleavable
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Antibody Drug Conjugates Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Application (2020-2032)
10.1.2. Market Revenue and Forecast, by Technology (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Application (2020-2032)
10.1.3.2. Market Revenue and Forecast, by Technology (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Application (2020-2032)
10.1.4.2. Market Revenue and Forecast, by Technology (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Application (2020-2032)
10.2.2. Market Revenue and Forecast, by Technology (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Application (2020-2032)
10.2.3.2. Market Revenue and Forecast, by Technology (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Application (2020-2032)
10.2.4.2. Market Revenue and Forecast, by Technology (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Application (2020-2032)
10.2.5.2. Market Revenue and Forecast, by Technology (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Application (2020-2032)
10.2.6.2. Market Revenue and Forecast, by Technology (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Application (2020-2032)
10.3.2. Market Revenue and Forecast, by Technology (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Application (2020-2032)
10.3.3.2. Market Revenue and Forecast, by Technology (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Application (2020-2032)
10.3.4.2. Market Revenue and Forecast, by Technology (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Application (2020-2032)
10.3.5.2. Market Revenue and Forecast, by Technology (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Application (2020-2032)
10.3.6.2. Market Revenue and Forecast, by Technology (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Application (2020-2032)
10.4.2. Market Revenue and Forecast, by Technology (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Application (2020-2032)
10.4.3.2. Market Revenue and Forecast, by Technology (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Application (2020-2032)
10.4.4.2. Market Revenue and Forecast, by Technology (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Application (2020-2032)
10.4.5.2. Market Revenue and Forecast, by Technology (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Application (2020-2032)
10.4.6.2. Market Revenue and Forecast, by Technology (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Application (2020-2032)
10.5.2. Market Revenue and Forecast, by Technology (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Application (2020-2032)
10.5.3.2. Market Revenue and Forecast, by Technology (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Application (2020-2032)
10.5.4.2. Market Revenue and Forecast, by Technology (2020-2032)
Chapter 11. Company Profiles
11.1. Takeda Pharmaceutical Company Limited
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Pfizer Inc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. GlaxoSmithKline Plc
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. AstraZeneca
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Seagen Inc
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. ADC Therapeutics
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Gilead Sciences Inc
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. F. Hoffmann-La Roche Ltd
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments